Trial Profile
An open label phase II trial of rituximab (IDEC-C2B8) in patients with mantle cell lymphoma, lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinaemia and small lymphocytic lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2005
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Roche
- 03 Aug 2005 New trial record.